Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR: AZD4831 in heart failure with LVEF > 40%
jRCT2031210194Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in KCCQ-TSS at Week 16 (Part A), Change from baseline in 6-minute walk distance at Week 16 (Part A) and 2 more. Started Oct 2021; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2031210194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210194.